SEPN
Septerna Inc · Healthcare · Biotechnology
Momentum inputs (comparable managers):
holder breadth -8.3% ·
share flow +11.4% ·
net new positions -9.1%
· formula
Concentrated accumulation: rising shares among fewer holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q3 2025
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | The Vanguard Group ✦ (passive) | 1.52M | +7.4% | $28.57M | 0.0% | ▲ Add | 2 | SEC ↗ ×3 |
| 2 | BlackRock ✦ (passive) | 1.46M | +5.0% | $27.46M | 0.0% | ▲ Add | 2 | SEC ↗ ×7 |
| 3 | Goldman Sachs Group ✦ | 1.45M | n/a | $27.36M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 4 | Geode Capital Management ✦ (passive) | 545.70K | +11.8% | $10.27M | 0.0% | ▲ Add | 4 | SEC ↗ ×2 |
| 5 | State Street Global Advisors ✦ (passive) | 418.96K | +13.2% | $7.88M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 6 | Millennium Management ✦ | 384.20K | +639.6% | $7.23M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 7 | Two Sigma Investments ✦ | 92.33K | +18.9% | $1.74M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 8 | Morgan Stanley ✦ | 54.46K | n/a | $1.02M | 0.0% | n/c | 1 | SEC ↗ ×5 |
| 9 | T. Rowe Price ✦ | 27.42K | +10.1% | $516,000 | 0.0% | ▲ Add | 4 | SEC ↗ |
| 10 | JPMorgan Chase ✦ | 17.47K | n/a | $328,648 | 0.0% | n/c | 1 | SEC ↗ ×6 |
| 11 | Fidelity (FMR) ✦ | 3.44K | +38.4% | $64,669 | 0.0% | ▲ Add | 2 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| Citadel Advisors | $187,871 | was 0.0% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 123 holders, 45.64M shares, $1.09B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer · 2.91K sh · $109,307
Officer · 1.09K sh · $40,337
10% owner · 141 sh · $7,202
Director, 10% owner · 746.50K sh · $31.73M
Director, 10% owner · 746.50K sh · $31.73M
10% owner · 147.06K sh · $7.39M
Officer · 25.00K sh · $1.10M
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology
11.8% of class · View original SEC filing ↗